Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- VSC.F
- Price
- 2.50
- Stock movement up
- +- (%)
- Company name
- 4SC AG
- Exchange
- (F ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 25.29M
- Ent value
- 21.32M
- Price/Sales
- -
- Price/Book
- 5.00
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 8.18%
- 1 year return
- -68.51%
- 3 year return
- 9.39%
- 5 year return
- -22.86%
- 10 year return
- -22.38%
Last updated: 2025-04-05
DIVIDENDS
VSC.F does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 5.00 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 10.11M |
| EPS (TTM) | - |
| FCF per share (TTM) | -0.05 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | 0.00 |
| Net income (TTM) | 0.00 |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 8.32M |
| Net receivables | 161.00K |
| Total current assets | 8.75M |
| Goodwill | 0.00 |
| Intangible assets | 633.00K |
| Property, plant and equipment | 646.00K |
| Total assets | 9.40M |
| Accounts payable | 383.00K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 3.69M |
| Total liabilities | 4.35M |
| Shareholder's equity | 5.05M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -513.50K |
| Capital expenditures (TTM) | 1.50K |
| Free cash flow (TTM) | -515.00K |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | -10.19% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.50 |
| Daily high | 2.50 |
| Daily low | 2.50 |
| Daily Volume | 0K |
| All-time high | 136.25 |
| 1y analyst estimate | 5.50 |
| Beta | 1.67 |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 16 Apr 2025 |
Downside potential
Loading...
Downside potential data
| VSC.F | S&P500 | |
| Current price drop from All-time high | -98.17% | -12.44% |
| Highest price drop | -99.18% | -56.47% |
| Date of highest drop | 13 Jul 2022 | 9 Mar 2009 |
| Avg drop from high | -71.98% | -11.07% |
| Avg time to new high | 306 days | 12 days |
| Max time to new high | 4811 days | 1805 days |
COMPANY DETAILS
Marketcap
25.29M
Marketcap category
Small-cap
Description
4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany. Its product Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma, which is in clinical development stage. The company also out-licenses its products to pharma and biotech companies. The company was founded in 1997 and is headquartered in Planegg, Germany.
Employees
15
Website
Investor relations
-
SEC filings
CEO
Country
Germany
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
4SC AG progresses with Resminostat's EU marketing application while navigating financial hurdles and strategic market entry plans.
October 9, 2024